efalizumab Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
humanized origin 4959 214745-43-4

Description:

MoleculeDescription

Synonyms:

  • efalizumab
  • raptiva
  • hu1124
  • anti-CD11a
  • xanelim
a humanized anti-CD11anti-adhesion monoclonal antibody
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
10 mg P

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Sept. 20, 2004 EMA
Oct. 27, 2003 FDA GENENTECH

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Psoriasis 458.42 33.68 147 1370 78457 46606088
Skin plaque 55.24 33.68 16 1501 5819 46678726
Skin exfoliation 55.03 33.68 25 1492 32913 46651632
White blood cell count increased 50.92 33.68 26 1491 44193 46640352
Lymphocyte count increased 46.76 33.68 12 1505 2778 46681767
Enzyme level increased 41.79 33.68 7 1510 196 46684349

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Psoriasis 378.75 30.26 126 1583 42380 29908389
Erythrodermic psoriasis 90.60 30.26 18 1691 744 29950025
Psoriatic arthropathy 62.56 30.26 26 1683 15735 29935034
White blood cell count increased 60.68 30.26 34 1675 39639 29911130
Papillary cystadenoma lymphomatosum 41.11 30.26 6 1703 35 29950734
Dermatitis exfoliative 38.93 30.26 15 1694 7441 29943328
Meningitis aseptic 33.40 30.26 10 1699 2312 29948457
Condition aggravated 31.59 30.26 39 1670 137827 29812942
Influenza like illness 31.29 30.26 19 1690 25586 29925183
Lymphocytosis 30.58 30.26 9 1700 1961 29948808
Arthralgia 30.45 30.26 38 1671 135753 29815016

Pharmacologic Action:

SourceCodeDescription
ATC L04AA21 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
IMMUNOSUPPRESSANTS
IMMUNOSUPPRESSANTS
Selective immunosuppressants
FDA CS M0001357 Antibodies, Monoclonal
FDA MoA N0000175856 CD11a-directed Antibody Interactions
FDA EPC N0000175858 CD11a-directed Humanized IgG1 Antibody

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Plaque psoriasis indication 200965009

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Leukocyte adhesion glycoprotein LFA-1 alpha Adhesion ANTIBODY BINDING Kd 11.40 IUPHAR DRUG LABEL

External reference:

IDSource
D03959 KEGG_DRUG
4021411 VUID
N0000148826 NUI
4021411 VANDF
C1174995 UMLSCUI
CHEMBL1201575 ChEMBL_ID
DB00095 DRUGBANK_ID
C472181 MESH_SUPPLEMENTAL_RECORD_UI
6593 IUPHAR_LIGAND_ID
8122 INN_ID
XX2MN88N5D UNII
356988 RXNORM
17649 MMSL
47678 MMSL
d04902 MMSL
005208 NDDF
407005009 SNOMEDCT_US
407006005 SNOMEDCT_US

Pharmaceutical products:

None